Multiple sclerosis (6)
multiple sclerosis (4)
generalized myasthenia gravis (2)
magnetic resonance imaging (2)
Ocrelizumab (2)
quality of life (2)
repetitive nerve stimulation (2)
Adult-onset multiple sclerosis (1)
Aging (1)
antineutrophil autoantibodies (1)
antinuclear autoantibodies (1)
anxiety (1)
Anxiety (1)
autoimmunity (1)
autonomic neuropathy (1)
cerebellar vermis (1)
cerebral palsy (1)
cerebral veins (1)
Cerebrospinal fluid (1)
Cladribine (1)
Clinical characteristics (1)
cognitive dysfunction (1)
Cognitive function (1)
Cognitive performance (1)
Cubital Tunnel Syndrome (1)
Decreased (1)
Decretion (1)
Demyelinating diseases (1)
depression (1)
Depression (1)
Diabetes mellitus (1)
digital health (1)
disease progression (1)
Disease progression (1)
Disease reactivation (1)
Disease-modifying therapies (DMTs) (1)
drug administration schedule (1)
Drug-related side effects and adverse reactions (1)
Electrodiagnosis (1)
electromyography (1)
Expanded disability status scale (EDSS) (1)
fatigue (1)
Fingolimod (1)
Fingolimod hydrochloride (1)
Functional outcomes (1)
gait disorders (1)
Hepatotoxicity (1)
IgG levels (1)
Immunoglobulin G (1)
Immunology (1)
Late -onset (1)
Late-onset multiple sclerosis (1)
Liver function tests (LFTs) (1)
Median Nerve (1)
Mental health (1)
Migraine (1)
mobility limitation (1)
MOGAD (1)
multiple sclerosis progression (1)
Myelin oligodendrocyte glycoprotein (1)
natalizumab (1)
neuroimaging (1)
Neuroimaging (1)
Neurology (1)
Neuromuscular disease (1)
Neuromyelitis optica spectrum disorders (1)
Neuropathic pain (1)
NMOSD (1)
Oligoclonal bands (1)
Pain management (1)
patient engagement (1)
Patient reported outcome (1)
patient reported outcomes (1)
Patient satisfaction (1)
Pediatric-onset multiple sclerosis (1)
personalized medicine (1)
Pregnancy (1)
prognosis (1)
Prognosis (1)
Psychological support (1)
Quality of life (1)
Recurrence (1)
Relapsing-remitting (1)
relapsing-remitting multiple sclerosis (1)
Relapsing-remitting multiple sclerosis (RRMS) (1)
respiratory function tests (1)
Restless genital syndrome (1)
restless leg syndrome (1)
Rhombencephalosynapsis (1)
R-R interval (1)
Social interaction (1)
Stigma (1)
telerehabilitation (1)
Transaminases (1)
trapezius muscle (1)
treatment adherence and compliance (1)
Treatment outcome (1)
Treatment response (1)
Treatment transition (1)
Turkey (1)
Ulnar Nerve (1)
vascular pathophysiology (1)
walking speed (1)
Washout period (1)
Wearing-off phenomenon (1)
Workplace challenges (1)
